



نقابة صيادلة لبنان
Order of Pharmacists of Lebanon

Under the Patronage of His Excellency
the Minister of Public Health

Dr. Firass Abiad

The Order of Pharmacists of Lebanon
is organizing the

25th
**PHARMACIST
DAY**

Lebanon Pharmaceutical Identity:
Towards a National Pharmaceutical Strategy

هوية لبنان الدوائية:

نحو استراتيجية وطنية للقطاع الصيدلاني



Sunday May 8, 2022
Le Royal Hotel, Beirut

**4 CE
Credits**



Lebanon
Pharma Group

نقابة مصانع الأدوية في لبنان
Syndicate of Pharmaceutical Industries in Lebanon



Organized by

sciencepro

Your Goal, Our Commitment

f @ in o t www.sciencepro.me



WELCOME NOTE



At the beginning of the twentieth century, and before the fall of the Ottoman Empire, the Lebanese tried to give meaning and justification to the existence of their Lebanon.

After the declaration of the state of Greater Lebanon, this emerging entity stood firm, and the identity triumphed despite all wars, tragedies, abolition attempts, occupation, and subjugation.

Lebanon preserved its identity thanks to its prominent clinging and commitment to playing its role as the Message, the meeting place of civilizations and religions, and the link between East and West. Lebanon's civilization (dating back to thousands of years and represented by the distinguished and leading universities, schools, hospitals, press and print media, and the intellectual, literary, and cultural freedoms) is its true identity, the source of its strength, and the more profound meaning and justification for its continued existence.

Today, instead of lamenting over the ruins, while Lebanon's history and civilization are collapsing before our eyes and the Lebanese patient is suffering, we, at the Order of Pharmacists of Lebanon, have decided that the rescue process begins by having all sectors endeavor to preserve their existence, each from their perspective and specialization.

In this regard, our goal is the healthcare sector, particularly the pharmaceutical sector; therefore, we are determined to propose a sustainable and realistic pharmaceutical strategy while collaborating with all key stakeholders and partners to secure good quality medications for the Lebanese patient by facing all challenges and creating innovative solutions related to the pharmaceutical supply chain.

As a consequence, medications will remain one of the most prominent features of civilization in Lebanon, and the pharmacist will remain the guardian of identity and entity...

Joe Salloum,

President, Order of Pharmacists of Lebanon.



Sunday May 8, 2022 - PROGRAM

09:00 - 10:30 **Registration**

10:30 - 12:00 **Opening Ceremony**

The Lebanese National Anthem

Address of Dr. Joe Salloum, President of the Order of Pharmacists of Lebanon
Address of H.E. Dr. Mohamad Abou Haidar, DG, Ministry of Economy & Trade
Address of H.E. M.P. Fadi Alame, Member of the Parliamentary Health Commission
Address of Dr. Iman Shankiti, WHO Representative to Lebanon
Address of H.E. Mr. George Bouchikian, Minister of Industry
Address of H.E. Mr. Abbas Halabi, Minister of Education and Higher Education
Address of H.E. Dr. Firass Abiad, Minister of Public Health

Distribution of Awards

12:00 - 12:15 **The National Pharmaceutical Strategy: An Overview**

Pr. Pascale Salameh, Chair of the OPL Scientific Committee

12:15 - 13:30 **Policy Dialogue**

Moderator: Pr. Pascale Salameh (OPL)

Panelists: Dr. Firass Abiad (Minister of Public Health), Dr. Rasha Hamra (WHO Lebanon),
Dr. Charaf Abou Charaf (LOP), Dr. Carole Hassoun (Chair, LPG), Dr. Carol Abi Karam (President, SPIL),
Mr. Karim Gebara (President, LPIA), Mr. Elie Nasnas (President, ACAL), Dr. Joe Salloum (President, OPL).

13:30 - 15:00 **Lunch**



Sunday May 8, 2022 - PROGRAM

15:00 - 17:00

Afternoon Sessions

Moderator: Dr. Luna El Bizri

15:00 - 15:20

FIP Vision Into Practice: Global Examples of Strategies to Enable Access to Quality Medications

Dr. Catherine Duggan

15:20 - 15:30

Q&A

15:30 - 15:50

Optimising Patient Access to Safe and Effective Medications

Dr. Ema Paulino

15:50 - 16:00

Q&A

16:00 - 16:20

Evidence, Policy, and Pharmaceutical Reform


Pr. Fadi El-Jardali

16:20 - 16:30

Q&A

16:30 - 17:00

Closing Remarks



BIOGRAPHY



Pr. Pascale Salameh
Chair of the OPL Scientific Committee

Currently a full Professor of Epidemiology at the Lebanese University, Faculties of Medicine, Pharmacy, Public Health, and Doctoral School of Sciences & Technologies. Quality Representative and Accreditation leader at the Lebanese University. Former Dean of the Faculty of Pharmacy, Lebanese University, and Former Associate Dean for Academic Affairs at the School of Pharmacy, Lebanese American University. Former and current Chair of the Scientific Committee at the Order of Pharmacists of Lebanon. Founder and Director of the Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie-Liban (INSPECT-LB). Expert in research direction with a diploma of Ability to Direct Research (HDR); long experience in research designing, data collection and management, and advanced statistical analysis. Has more than 500 publications in peer-reviewed journals and hundreds of oral presentations and scientific posters in medical epidemiology, clinical pharmacy, and public health.

Invited professor, adjunct professor, and research associate in several institutions at local and international levels: Lebanese American University - School of Medicine, Saint Joseph University - Faculty of Dental Medicine, Modern University of Business and Sciences, Université Libre de Bruxelles - Ecole de Santé Publique, Université Paris Est Créteil - Hôpital Henri Mondor, Charité – Universitätsmedizin Berlin, and University of Nicosia Medical School. Member of the International Pharmaceutical Federation (FIP).



Towards a National Pharmaceutical Strategy in Lebanon: A commitment and a Call to Action to Ensure Access to Quality and Safe Medications in Lebanon for All

Hala SACRE (OPL), Rasha HAMRA (WHO), Carole HASSOUN (LPG), Carol ABI KARAM (SPIL), Omar EL RIFAI (WHO), Pascale SALAMEH (OPL).

Background: Before 2019, the market was import-driven, with 93% of the products imported from around 40 countries. It is also brand-driven, with 68% of proprietary drugs mostly imported from Europe. Generic medications accounted for 60% of the market in volume and 45% in value. Compared to other parts of the world, expenditure on pharmaceuticals and out-of-pocket expenses were high. As of 2019, severe socioeconomic and health crises hit Lebanon related to political turmoil, the COVID-19 pandemic, and the Beirut port blast in 2020. All these led to the impoverishment of the population, limited access to foreign currency, severe shortages of medications, and deteriorated healthcare services.

Purposes: The aim of this work is to highlight the critical elements that should be addressed in the planned National Pharmaceutical Sector Strategy that the Order of Pharmacists of Lebanon (OPL) intends to develop, in consultation with the main concerned stakeholders. The ultimate goal is to secure timely access for all patients (“leaving no one behind”) to quality, affordable, and safe medications without suffering financial hardships.

Expected Outcomes: Local production and importation of quality-assured pharmaceutical products; a concrete and transparent mechanism for public funds and insurance companies/TPP to cover treatments based on Health Technology Assessment (HTA), and active participation of all stakeholders in assisting the Lebanese government/regulatory authority in developing and implementing a time-bound roadmap for the transition between MOPH and the LDA; a “new” role of MOPH as a “tutoring authority”; the development of a human resources strategy for the needs of local manufacturers through relevant training, education, and retention strategies; the rational use of medications by prescribers, dispensers, and patients; patient empowerment through awareness campaigns; Digitalization of all the steps related to the strategy, from development to waste management.

The Way Forward: Establish a national technical committee to identify priorities based on strategic goals, forecast expected challenges, and monitor the implementation progress.

Developing the national pharmaceutical strategy is a window of opportunity to attain excellence in pharmaceutical care.

BIOGRAPHY



Dr. Catherine Duggan

CEO

**International Pharmaceutical Federation
The Netherlands**

Dr. Catherine Duggan is the Chief Executive Officer of the International Pharmaceutical Federation and is responsible for visionary leadership, support, development, advocacy and growth across the 150 member organisations and the four million members FIP represents. In 2019, Dr. Duggan chaired the World Professions Health Alliance (represents 35 million health professionals across medicine, nursing, dentistry, physiotherapy and pharmacy) and signed the FIP MOU with WHO in May 2019 at the World Health Assembly meeting. Until April 2018, she was the Director of Professional Development at the Royal Pharmaceutical Society of Great Britain, where she was responsible for the delivery of professional advice and support to all members across all sectors; the development of strategies to share and showcase good practice across the profession and development and implementation of professional standards for pharmacy.

From 2012, Dr. Duggan led the development, implementation and strategic embedding of RPS Faculty and Foundation programmes into continuing professional development. She has published widely and presented at national and international meetings and has a wealth of people and programme management experience. Dr. Duggan is a recognised leader across the profession working with many networks within and across the profession and, more widely, health and business. She has worked in community, primary care, hospital and academia.

Between 2007 and 2009, Dr. Duggan was the Chair of the United Kingdom Clinical Pharmacy Association and then an elected member of the Council of the RPSGB. A double graduate from the School of Pharmacy, University of London (now UCL School of Pharmacy), she received a Fellowship of the School of Pharmacy, University of London in 2013, was awarded an honorary Professorship from the School of Pharmacy, University of Nottingham in 2018. Dr. Duggan has been awarded Fellowships of both the Royal Pharmaceutical Society and the Royal Society of Arts. In May 2021, Catherine was awarded the Nagai International Woman Scientist Award 2021, on behalf of the Academy of Pharmaceutical Science and Technology, Japan.



FIP Vision Into Practice: Global Examples of Strategies to Enable to Access to Quality Medications

Strategies to enable access to quality medicines

Dr. Catherine Duggan. PhD, FRPharmS, FRSA
Chief Executive Officer, International Pharmaceutical Federation (FIP).

The vision for FIP is for a world where everyone benefits from access to safe and effective medicines and pharmaceutical care. To deliver the vision, the mission of FIP is to improve global health by supporting the advancement of pharmaceutical practice, sciences and education.

The access to quality medicines is central to FIP. In 2008, FIP launched a vision to take it to 2020 and stated wherever and whenever decision makers discuss any aspects of medicines on a global level, FIP is at the table and it is therefore an imperative that FIP supports its members and the profession to do the same wherever and whenever decision makers discuss any aspects of medicines on a national level, pharmacy is at the table.

In 2016, FIP Ed described future professional directions and how education supports evolution of practice and science, in response to workforce challenges outlined by WHO. “Through this Vision, FIP seeks to support and develop high standards of education and training and to promote and protect the health and wellbeing of civil society through leadership and development of our professional workforces and to ensure our contribution to the health and wellbeing of patients”. This vision was supported by the 13 FIP workforce development goals.

In 2018, we signed the profession up to the Astana declaration, ensuring pharmacy plays its part in delivering Universal Health Coverage through primary health care. We identified the three areas of practice and focus to ensure we deliver our commitment to the Astana declaration. The FIP primary health care strategy is that there is no primary health care without prevention, long term condition management, self-care and acute exacerbation. There is NO primary health care without pharmacy IN ALL SECTORS. There is a part for our entire profession can play, and we have seen this so clearly during the COVID-19 pandemic.

During the 72nd World Health Assembly in May 2019, FIP signed the FIRST Memorandum of Understanding between FIP and WHO to strengthen partnership around workforce, patient safety, primary health care and other areas. We then undertook to build on the FIP WDGs to develop the 21 FIP Development Goals and reiterate FIP’s commitment to global health. Central to this and our vision is the goal for equity of access.

For us to deliver on these 21 goals, we need to demonstrate impact, we need to demonstrate impact with evidence and intelligence and for this evidence, we need data. The 18th DG is focussed on access and the presentation will outline the ways in which we can support Strategies to enable access to quality medicines.

BIOGRAPHY



Dr. Ema Paulino

President

**National Association of Pharmacies
Portugal**

Dr. Ema Paulino is a practising pharmacist at her own community pharmacy in Portugal. She is General Manager of Ezfy, a company that engages community pharmacies in the implementation of Patient Support Programmes. Dr. Paulino is President of the Portuguese National Association of Pharmacies (ANF) and was a member of the National Board of the Portuguese Pharmaceutical Society (PPS) until June 2021.

She represents ANF at various international groups and organisations such as the Pharmaceutical Group of the European Union (PGEU) and the International Pharmaceutical Federation (FIP). Dr. Paulino is Immediate past-Professional Secretary of FIP, and thus a member of its Executive Committee and Bureau until September 2021.

She has previously been Chairperson and Project Coordinator of the Young Pharmacists' Group, a member of the FIP Programme Committee, and Secretary of the Community Pharmacy Section. Dr. Paulino is currently the Chairperson of the Pharmaceutical Care Network Europe (PCNE), and a member of the Board of the International Primary Care Respiratory Group (IPCRG).



Optimising Patient Access to Safe and Effective Medications

Dr. Ema Paulino
President, National Association of Pharmacies, Portugal.

Over the centuries, there have been many challenges that the pharmaceutical profession, and the community pharmacy as a field of practice, faced in an optimistic and constructive way. We have always been part of the solution to demographic changes, the change in the burden of the disease, and the technological development that accompanies the restlessness of a society that is not satisfied with the status quo. The cycles of change, however, become shorter and shorter. And the expectations of citizens and health systems increase in proportion to their knowledge of the potential, but sometimes not demonstrated (perceived?) value, of the health professionals with whom they interact. Our interpretation of what a pharmacy is today, due to the limitations of its physical space, will inevitably evolve. The pharmacy will occupy the space that it is able to build, in person, but also virtually. Accompanying people on their health care journey will require this. Because we believe that behind an effective and safe medicine, you will always find an attentive, proactive pharmacist, who assumes his responsibility as an integral part of the healthcare team. But it will depend entirely on ourselves. What we do on a day-to-day basis, the way we manage our resources and infrastructures, the partners we choose to work with, the movements we join. This presentation will focus and present how community pharmacy practice has evolved in the past decade, and what envisioned future we are building for ourselves.

BIOGRAPHY



Pr. Fadi El-Jardali

**Director K2P Center
American University of Beirut
Lebanon**

Professor Fadi El-Jardali (PhD, MPH) is a recognized senior expert with extensive international and regional experience and multidisciplinary background in health policy, systems and management. He is a Professor of Health Systems and Policy, former Chair of the Health Management and Policy Department, Founder & Director of the Knowledge to Policy (K2P) Center; Director of the World Health Organization (WHO) Collaborating Center for Evidence-Informed Policy and Practice; Co-Director of the Center for Systematic Reviews in Health Policy and Systems Research (SPARK); and co-lead for the Global Evidence Synthesis Initiative (GESI) Secretariat at the American University of Beirut. He is part time Professor at McMaster University in Canada. He is also the Co-Editor in Chief for Health Research, Policy and Systems (HARPS) Journal.

Dr. El-Jardali is a recipient of the Global Health Leadership Award and was elected twice to the Board of Health Systems Global Society. He is a recipient of the Fellowship on Evidence Informed Policy from the Alliance for Health Policy and Systems Research. He is the founding member of the MENA Health Policy Forum. He is a member of the Global Steering Committee for the WHO Evidence-Informed Policy Network (EVIPNet). He has served on other high level committees in United Nations Organizations, Wellcome Trust, etc.

His research is connected to real world health systems and priorities and grounded in the practical understanding of economic, social, environmental and political realities, constraints and context. He has published extensively on health systems and policy (more than 130) in international peer review and impact factor journals in addition to book, book chapters, and several knowledge translation products on policy priority areas. He supported several governments, professional associations, and health care organizations with many impactful initiatives.

Before joining academia, Fadi has worked and held senior positions with policy analysis related organizations in Canada such as the Ontario Ministry of Health and Long-Term Care (as Hospital Consultant), Federal department of health / Health Canada (as Senior Policy Advisor) and the Health Council of Canada. He was also a hospital CEO.



Evidence, Policy, and Pharmaceutical Reform

Dr. Fadi El-Jardali

Director K2P Center, American University of Beirut, Lebanon.

In his presentation, Dr. El-Jardali will re-iterate the importance of establishing a National Pharmaceutical Strategy in Lebanon given the unprecedented multiple challenges facing the health sector in the country and the policy window of opportunity to act now if we are to attain better health outcomes and contribute effectively to universal health coverage through universal and sustainable access to quality and affordable medications. Following a brief recap of the situation in Lebanon, the presentation will draw on the experiences and best practices from other countries that underwent reform (including the added value of strengthening local pharmaceutical industry, promoting generic drug use, regulating physician-pharma interactions etc.) and the impacts achieved in terms of accessibility, quality and costs (including broader economic yield).

The presentation will highlight the important role of evidence in informing the pharmaceutical reform in Lebanon and the need to build and translate evidence and best practices into actual policies and actions. A particular emphasis will be on the implementation phase which is a historically weak link in Lebanon. By learning from failures of previous policies in Lebanon and building on successes from other countries, the presentation will conclude with recommendations and way forward to strengthen the pharmaceutical sector in Lebanon.